down arrow

NanoViricides, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6300873022
USD
1.22
0.11 (9.91%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.101.25

52 Week

0.942.22
Valuation
Technical
Day's Volume

CASH

329.02 k

Shareholding (Mar 2025)

FII

1.68%

Held by 8 FIIs

DII

93.76%

Held by 5 DIIs

Promoter

0.00%

How big is NanoViricides, Inc.?

22-Jun-2025

As of Jun 24, NanoViricides, Inc. has a market capitalization of 21.54 million, with net sales of 0.00 million and a net profit of -9.74 million over the latest four quarters. Shareholder's funds are 11.46 million and total assets are 12.82 million.

As of Jun 18, NanoViricides, Inc. has a market capitalization of 21.54 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 24, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -9.74 million.<BR><BR>As of Jun 24, the reporting period shows Shareholder's Funds at 11.46 million and Total Assets at 12.82 million.

Read More

What does NanoViricides, Inc. do?

22-Jun-2025

NanoViricides, Inc. is a nano-biopharmaceutical company focused on developing drugs for viral infections, with a market cap of $21.54 million and a recent net profit of -$2 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.

Overview:<BR>NanoViricides, Inc. is a nano-biopharmaceutical research and development company engaged in the discovery, development, and commercialization of drugs to combat viral infections, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 21.54 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.29<BR>- Return on Equity: -110.12%<BR>- Price to Book: 2.44<BR><BR>Contact Details:<BR>- Address: 1 Controls Dr, SHELTON CT: 06484-6153<BR>- Tel: 1 203 9376137<BR>- Fax: 1 203 8595095<BR>- Website: http://www.nanoviricides.com/

Read More

Who are in the management team of NanoViricides, Inc.?

22-Jun-2025

As of March 2022, the management team of NanoViricides, Inc. includes Dr. Anil Diwan as Executive Chairman and President, along with independent directors Mr. Stanley Glick, Mr. Makarand Jawadekar, Mr. Theodore Rokita, and Mr. Brian Zucker.

As of March 2022, the management team of NanoViricides, Inc. includes Dr. Anil Diwan, who serves as the Executive Chairman of the Board and President. Additionally, the Board of Directors features several independent directors: Mr. Stanley Glick, Mr. Makarand Jawadekar, Mr. Theodore Rokita, and Mr. Brian Zucker.

Read More

Is NanoViricides, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, NanoViricides, Inc. shows a mildly bullish trend in the short term, but caution is advised due to mixed signals from weekly indicators and underperformance compared to the S&P 500.

As of 10 September 2025, the technical trend for NanoViricides, Inc. has changed from sideways to mildly bullish. However, the overall stance remains mixed, with the weekly MACD and RSI indicating bearish signals, while the monthly MACD shows a mildly bullish trend. The daily moving averages are mildly bullish, suggesting short-term strength. Despite this, the stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -14.46% compared to the S&P 500's 17.14%. Overall, the technical stance is mildly bullish but with significant caution due to bearish indicators in the weekly timeframe.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 23 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.29

stock-summary
Return on Equity

-110.12%

stock-summary
Price to Book

2.62

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.27%
0%
-11.27%
6 Months
-22.29%
0%
-22.29%
1 Year
-11.59%
0%
-11.59%
2 Years
3.74%
0%
3.74%
3 Years
-27.81%
0%
-27.81%
4 Years
-72.65%
0%
-72.65%
5 Years
-68.48%
0%
-68.48%

NanoViricides, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is NanoViricides, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for NanoViricides, Inc. has changed from sideways to mildly bullish. However, the overall stance remains mixed, with the weekly MACD and RSI indicating bearish signals, while the monthly MACD shows a mildly bullish trend. The daily moving averages are mildly bullish, suggesting short-term strength. Despite this, the stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -14.46% compared to the S&P 500's 17.14%. Overall, the technical stance is mildly bullish but with significant caution due to bearish indicators in the weekly timeframe....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-4.01%
EBIT to Interest (avg)
-8.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.41%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.80
EV to EBIT
-2.25
EV to EBITDA
-2.44
EV to Capital Employed
3.53
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-156.86%
ROE (Latest)
-110.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (4.56%)

Foreign Institutions

Held by 8 Foreign Institutions (1.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -15.79% vs -11.76% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-1.70",
          "chgp": "-23.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-1.90",
          "chgp": "-15.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 3.49% vs -6.17% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.80",
          "val2": "-8.20",
          "chgp": "4.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.30",
          "val2": "-8.60",
          "chgp": "3.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.10
-1.70
-23.53%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.20
-1.90
-15.79%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -15.79% vs -11.76% in Mar 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'24stock-summary
Jun'24
Jun'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.80
-8.20
4.88%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.30
-8.60
3.49%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 3.49% vs -6.17% in Jun 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About NanoViricides, Inc. stock-summary
stock-summary
NanoViricides, Inc.
Pharmaceuticals & Biotechnology
NanoViricides, Inc. is a nano-biopharmaceutical research and development company. The Company is engaged the discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company provides nanoviricide technology, which enables direct attacks at multiple points on a virus particle. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. The nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company’s lead product candidate is NV-HHV-101 in the HerpeCide program, as a skin cream for the treatment of shingles rash.
Company Coordinates stock-summary
Company Details
1 Controls Dr , SHELTON CT : 06484-6153
stock-summary
Tel: 1 203 9376137
stock-summary
http://www.nanoviricides.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."